• Principal Investigator: A prospective, double-masked, randomized, multicenter, active- controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03% / timolol 0.5% ) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3)

• Principal Investigator: A phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops (bimatoprost 0.03% / timolol 0.5%) to Taptiqom® eye drops (tafluprost 0.0015% / timolol 0.5%).

• Principal Investigator: Clinical performance of Compass in the diagnosis of glaucoma: a comparision with HFA (CMP_002)

• Principal Investigator: To evaluate the efficacy, safety and tolerability of Bimatoprost 0.01% (BIMMD) and Tafluprost single-dose 15 µg / ml (TUDPF) (SAFLUTAN) in patients with glaucoma or ocular hypertension suitable for prostaglandin therapy: European multicentre, randomized, cross study – over, single blind, with a masked investigator, lasting six months. (SPORT II)

• Principal Investigator: Safety and efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV)

• Principal Investigator: XEN GLAUCOMA TREATMENT REGISTER (XEN-GTR): Italian multicenter prospective observational study

• Principal Investigator: Efficacy of an ophthalmic solution based on aturine and hyaluronic acid in glaucoma and ocular hypertensive patients in chronic therapy with ocular hypotonizing drugs (OFTAL PLUS)

•Principal Investigator: Combination of tafluprost 0.0015% / timolol 0.5% without preservative, fixed dose, in patients with open angle glaucoma or ocular hypertension: clinical efficacy, tolerability and safety in a real life scenario. (0240-0024) LOYADA

• Principal Investigator: Evaluation of BDNF and NGF levels in plasma and tears of glaucoma patients.

• Comparison between the incidence and severity of conjunctival hyperemia associated with the topical use of bimatoprost 0.01% and latanoprost 0.005% in glaucomatous or ocular hypertensive patients

• Comparison between the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure

• Principal Investigator: Proteomic study of the sclero-corneal trabeculae in glaucoma

• Principal Investigator: Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular hypertension or glaucoma: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial (SPORT)

• Principal Investigator: Efficacy of an ophthalmic solution based on cyanocobalamin, taurine and hyaluronic acid in patients treated with ocular hypotonizing drugs

• Principal Investigator: Diagnostic Accuracy of the Heidelberg Retinal Tomograph 3

• Principal Investigator: Multicenter study on age-related biomechanical changes of the cornea

• Principal Investigator: Comparison between the Moorfields Multi Location Motion Displacement test (MDT) and conventional perimetry in healthy eyes and sheared glaucoma

• Principal Investigator: Study of the epidemiology of glaucomatous disease in the urban population of the city of Rome

• Principal Investigator: Change in the morphological and functional patterns of the ocular surface in patient treated with latanoprost after the use of TSP 0,5% preservative free eyedrops. Randomized, prospective, single masked, multicenter study

• Comparison of the effect of bimatoprost-timolol fixed combination in reducing intraocular pressure versus fixed combinations of carbonic anhydrase inhibitors-timolol in patients with glaucoma or ocular hypertension not controlled by monotherapy: retrospective study

• Influence of pupillary dilation in measurements of the retinal nerve fiber layer (RNFL), the optic nerve head (ONH) and the ganglion cell layer (GCC) with Optical Coherence Tomography (OCT) Spectral Domain (RTVue-100)

• Learning effect of the Heidelberg Edge Perimeter (HEP) in patients with ocular hypertension.

• Prot. N ° 006-02-Prospective longitudinal study for the evaluation of the development of diseases on the ocular surface. Comparison between Treatment-Naive patients (not having received specific treatments) with ocular hypertension or glaucoma versus patients without elevated ocular pressure. (SAHARA)

• Evaluation of the genetic characteristics of pigment dispersion syndrome and pigmentary glaucoma and in other forms of glaucoma

• Multi-center clinical study of 2×3 months, single blind, comparing Ganfort and Duotrav in reducing intaocular pressure in patients with Pseudoexfoliative Glaucoma or Primary Open Angle Glaucoma treated with Xalacom.

• Cirrus-OCT reproducibility and accuracy

• European retrospective study on the rate of progression of open angle glaucoma

• Single-blind, multicenter, three-month pilot study to evaluate the efficacy and safety of the fixed combination bimatoprost / timolol vs latanoprost in previously untreated patients with open-angle glaucoma at high risk of glaucomatous disease progression

• Learning effect of sita-swap perimetry (swedish interactive algorithm short-wavelength) in patients with ocular hypertension